Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HCC1806 Topotecan
0.031667
Topo I
Chemotherapy
 -0.1410 0.36642
HCC1806 Topotecan
0.1
Topo I
Chemotherapy
 -0.1930 0.45120
HCC1806 Topotecan
0.31623
Topo I
Chemotherapy
 -0.3166 0.52031
HCC1806 Topotecan
1.0
Topo I
Chemotherapy
 -0.4557 0.51347
HCC1806 Topotecan
3.1623
Topo I
Chemotherapy
 -0.5081 0.50830
HCC1806 Topotecan
10.0
Topo I
Chemotherapy
 -0.5458 0.55016
HCC1806 Etoposide
0.0010833
Topo II
Chemotherapy
 1.0669 -0.00367
HCC1806 Etoposide
0.0033333
Topo II
Chemotherapy
 1.0136 -0.01034
HCC1806 Etoposide
0.01
Topo II
Chemotherapy
 0.9215 0.01352
HCC1806 Etoposide
0.031667
Topo II
Chemotherapy
 0.8408 0.02524
HCC1806 Etoposide
0.1
Topo II
Chemotherapy
 0.4365 0.06499
HCC1806 Etoposide
0.31623
Topo II
Chemotherapy
 0.0532 0.26506
HCC1806 Etoposide
1.0
Topo II
Chemotherapy
 -0.2399 0.40223
HCC1806 Etoposide
3.1623
Topo II
Chemotherapy
 -0.4171 0.47329
HCC1806 Etoposide
10.0
Topo II
Chemotherapy
 -0.5629 0.58641
HCC1806 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 0.9193 0.01548
HCC1806 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 0.9316 0.00249
HCC1806 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.9231 0.01466
HCC1806 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.6792 0.04311
HCC1806 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.2990 0.14756
HCC1806 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 -0.0810 0.31128
HCC1806 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 -0.1363 0.32774
HCC1806 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 -0.0635 0.25574
HCC1806 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 -0.0992 0.34463
HCC1806 Trametinib
0.0001
MEK
MAPK/nRTK
 1.0301 0.00613